Generic drugs are medications that are created to be equivalent to brand-name drugs in terms of dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. They are typically introduced to the market after the patent protections for the brand-name drugs have expired, allowing other manufacturers to produce and sell them. In this blog, we discuss the regulatory challenges faced by generic drugs.
Generic drugs are typically approved through an Abbreviated New Drug Application (ANDA) process by the US FDA. This pathway is designed specifically for generic drug approval and has distinct features compared to the New Drug Application (NDA) process used for brand-name drugs.
The European Medicines Agency (EMA) and national regulatory authorities in individual EU countries are responsible for generic drug approvals, often through the decentralized or centralized procedure.
Key features of the generic drug approval process:
No Requirement for Clinical Trials: Unlike an NDA, the ANDA does not require the generic manufacturer to conduct clinical trials to establish safety and efficacy.
Bioequivalence Testing: The manufacturer must conduct bioequivalence studies to prove that the generic drug performs in the same manner as the original drug, with similar pharmacokinetic properties.
Therapeutic Equivalence: The goal is to ensure that the generic drug can be substituted for the brand-name drug with the expectation that it will produce the same clinical effect.
Same Labeling as Brand-Name Drug: The generic drug must have the same labeling as the brand-name drug.
These approval processes are designed to streamline the approval of generic drugs, ensuring that they are safe, effective, and affordable alternatives to brand-name medications.
Regulatory challenges for generic drugs before market entry
Patent Certifications
As part of the ANDA, the generic manufacturer must certify how their drug relates to any patents on the brand-name drug. This includes:
Paragraph I: The drug is not patented.
Paragraph II: The patent has expired.
Paragraph III: The generic manufacturer will not market the drug until the patent expires.
Paragraph IV: The patent is invalid or will not be infringed by the generic drug (often leads to litigation).
Patent Challenges
Brand-name drug manufacturers often hold multiple patents on different aspects of a drug, including formulation, method of use, and production processes. Generic companies must navigate these patents and often face litigation when they attempt to enter the market.
30-Month Stay
If a generic manufacturer files a Paragraph IV certification (claiming that the brand’s patent is invalid or not infringed), the brand-name company can sue, which may result in an automatic 30-month stay, delaying the generic’s market entry.
Regulatory Exclusivities
Exclusivity Periods: Certain regulatory exclusivities can delay generic entry even after patent expiry. These include:
New Chemical Entity (NCE) Exclusivity: Provides 5 years of market exclusivity for drugs with a new active ingredient.
Orphan Drug Exclusivity: Grants 7 years of exclusivity for drugs treating rare diseases.
Pediatric Exclusivity: An additional 6 months of exclusivity may be granted if pediatric studies are conducted.
180-Day Exclusivity for First Generic (First-to-File Incentive): The first generic manufacturer to submit a substantially complete ANDA with a Paragraph IV certification may be granted 180 days of market exclusivity. During this period, no other generic can be marketed. This is an incentive for generic manufacturers to challenge patents and bring generics to market promptly.
Labeling Requirements
Labeling Parity: Generic drugs must have the same labeling as the brand-name drug, except for any differences allowed by the FDA. Ensuring this parity while also addressing any updates to the brand’s labeling can be complex.
Risk Evaluation and Mitigation Strategies (REMS): If the brand-name drug has an approved REMS, the generic must comply with the same requirements, which can complicate the approval process.
International Regulatory Variations
Harmonization: Regulatory requirements differ between countries. Navigating the different regulatory environments in major markets like the U.S., EU, and emerging markets can be challenging.
In conclusion, the regulatory challenges in bringing generic drugs to market after patent expiry are complex and multifaceted. Manufacturers must navigate a stringent approval process. Patent litigation, exclusivity periods, and supply chain issues further complicate the path to market. Despite these hurdles, overcoming these challenges is essential for ensuring that affordable, high-quality generics become available to patients, ultimately benefiting public health and fostering competition in the pharmaceutical industry. A robust regulatory strategy is key to successfully navigating these challenges and bringing generics to market efficiently.
Don’t let regulatory hurdles slow you down—reach out to Artixio at info@artixio.com today and take the first step towards successful product launches.
References:
Comments